Health-related quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is not different than cytoreductive surgery alone in primary ovarian cancer patients
GYNECOLOGIC ONCOLOGY(2023)
摘要
Adding hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery (CRS) raises concerns about poor health-related quality of life (HRQOL) outcomes in ovarian cancer (OC) patients. CRS/HIPEC has not been shown to decrease long-term HRQOL in other malignancies; however, the evidence in OC is inconsistent. We analyzed the HRQOL outcomes of primary OC patients with peritoneal metastasis (PM) enrolled in phase II randomized study (NCT#: 02124421).
更多查看译文
关键词
primary ovarian cancer patients,cytoreductive surgery,hyperthermic intraperitoneal chemotherapy,ovarian cancer,health-related
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要